Table 2 Demographic and 24-h MII-pH Data and HRM Parameters of 320 Patients with GERD Symptoms according to GEFV Grade.

From: Correlation between gastroesophageal flap valve abnormality and novel parameters in patients with gastroesophageal reflux disease symptoms by the lyon consensus

 

GEFV I (n = 94)

GEFV II (n = 145)

GEFV III (n = 40)

GEFV IV (n = 41)

P-value

Normal GEFV (n = 239)

Abnormal GEFV (n = 81)

P-value

Age

56.0(51.0–63.0)

61.0(52.0–67.0)

59.0(48.5–65.0)

67.0(54.5–77.5)

0.001

60.0(51.0–66.0)

63.0(51.5–71.5)

0.031

Male gender, n(%)

20(21.3%)

50(34.5%)

17(42.5%)

22(53.7%)

0.002

70 (29.3%)

39(48.1%)

0.002

BMI

23.0 ± 3.8

24.0 ± 3.7

23.3 ± 3.9

24.5 ± 3.5

0.092

23.6 ± 3.7

23.9 ± 3.8

0.556

24 h pH-MII parameters

AET%

0.9(0.2–2.9)

1.7(0.6–4.8)

1.5(0.3–4.2)

6.8(3.7–10.3)

 < 0.001

1.3(0.3–4.2)

4.2(1.5–7.4)

 < 0.001

Upright AET (%)

0.9(0.2–3.1)

2.5(0.6–6.1)

1.8(0.5–5.6)

7.3(3.9–11.1)

 < 0.001

1.5(0.4–5.0)

4.9(1.3–9.4)

 < 0.001

Recumbent AET (%)

0.1(0.0–0.6)

0.3(0.0–1.4)

0.5(0.0–1.4)

4.9(1.6–10.9)

 < 0.001

0.2(0–1.4)

1.6(0.1–5.7)

 < 0.001

MNBI(Ω)

2205.1(1944.4–2739.0)

2270.6(1777.1–2647.9)

2147.3(1662.6–2588.8)

1922.8(1514.7–2329.7)

0.015

2228.5(1794.8–2705.3)

2068.3(1658.4–2432.4)

0.012

PSPWI (%)

42.1(27.8–48.3)

29.9(23.3–38.4)

21.8(16.2–31.1)

18.2(11.7–28.2)

 < 0.001

33.3(25.0–44.0)

19.7(13.9–29.0)

 < 0.001

Bolus exposure (%)

0.5(0.3–0.8)

0.5(0.2–0.9)

0.6(0.3–1.2)

0.5(0.2–0.8)

0.608

0.5(0.2–0.9)

0.5(0.3–1.0)

0.635

Reflux event (n)

33.5(19.5–70.0)

36.0(17.5–59.0)

45.0(22.3–77.5)

40.0(21.5–69.5)

0.361

35.0(18.0–65.8)

43.5(22.0–76.0)

0.133

HRM parameters

 

EGJ tone

 

 EGJ-CI(mmHg.cm)

14.4(9.6–28.4)

16.8(11.4–25.4)

17.0(8.6–28.7)

17.9(12.1–24.4)

0.903

16.4(10.3–26.1)

17.7(10.6–24.5)

0.921

 EGJP-insp(mmHg)

42.9(27.9–59.7)

42.3(28.7–58.7)

39.3(23.3–58.2)

38.7(24.7–52.3)

0.548

42.3(28.3–59.3)

39.0(24.2–55.8)

0.155

 EGJP-exp(mmHg)

45.8(31.5–66.3)

41.3(25.0–59.8)

39.3(21.4–60.8)

45.0(27.7–55.8)

0.486

43.0(26.0–62.7)

41.3(24.0–58.0)

0.377

EGJ morphology

0.001

 

0.011

EGJ I

31(33.0%)

36(24.8%)

7(17.5%)

3(7.3%)

 

67(28.0%)

10(12.3%)

 

EGJ II

52(55.3%)

89(61.4%)

29(72.5%)

28(68.3%)

 

141(59.0%)

57(70.4%)

 

EGJ III

11(11.7%)

20(13.8%)

4(10.0%)

10(24.4%)

 

31(13.0%)

14(17.3%)

 

Esophageal body motility 0.077 0.216

Normal

40(42.6%)

59(40.7%)

17(42.5%)

12(29.3%)

 

99(41.4%)

29(35.8%)

 

Fragmented peristalsis

16(17.0%)

19(13.1%)

6(15.0%)

3(7.3%)

 

35(14.6%)

9(11.1%)

 

IEM

38(40.4%)

67(46.2%)

17(42.5%)

26(63.4%)

 

105(43.9%)

43(53.1%)

 

Endoscopy

 < 0.001

 

 < 0.001

Normal

77(81.9%)

30(20.7%)

12(30.0%)

3(7.3%)

 

107(44.8%)

15(18.5%)

 

LA-A&B

16(17.0%)

102(70.3%)

26(65.0%)

33(80.5)

 

118(49.4%)

59(72.8%)

 

LA-C&D&BE

1(1.1%)

13(9.0%)

2(5.0%)

5(12.2%)

 

14(5.9%)

7(8.6%)

 
  1. Values are presented as the median and interquartile range, except for BMI (mean and standard deviation), male gender, EGJ morphology, Esophageal body motility, and Endoscopy (n and %).
  2. MII-pH multichannel intraluminal impedance-pH, HRM high-resolution manometry, GERD gastroesophageal reflux disease, GEFV gastroesophageal flap valve, BMI body mass index, BE Barrett’s esophagus, AET acid exposure time, MNBI mean nocturnal baseline impedance, PSPWI post-reflux swallow-induced peristaltic wave index, EGJ esophagogastric junction, EGJ-CI EGJ-contractile integral, EGJP-insp inspiratory EGJ pressure, EGJP-exp expiratory EGJ pressure, IEM ineffective esophageal motility.
  3. P < 0.05 was considered to be significant.
Back to article page